Click here for slides on this topic


SAVOR-TIMI 53

Cardiovascular safety study of the DPP-4 inhibitor, saxagliptin. SAVOR-TIMI 53 is an acronym for Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53.
The following content matched the glossary term: SAVOR-TIMI 53

No Increased Risk of Pancreatic Cancer With Incretins

Top

Data presented at EASD 2015 show no causal association between the use of incretin based therapies—DPP-4 inhibitors and GLP-1 receptor agonists—and pancreatitis or pancreatic cancer

NDEI.org Expert Commentary Ed Horton, MD, on EMPA-REG OUTCOME Results

Top

Ed Horton, MD, discusses EMPA-REG OUTCOME results: SGLT2 inhibitor, empagliflozin, cuts CV deaths in high-risk type 2 diabetes patients

NDEI.org Expert Commentary Vivian Fonseca, MD, on EMPA-REG OUTCOME: Empagliflozin Cuts CV Deaths

Top

Vivian Fonseca, MD, discusses the impact of EMPA-REG OUTCOME; SGLT2 inhibitor, empagliflozin, reduced cardiovascular deaths in high-risk type 2 diabetes patients

Empagliflozin Cuts Cardiovascular Deaths in Landmark Trial

Top

The SGLT2 inhibitor, empagliflozin, reduces cardiovascular deaths in the EMPA-REG OUTCOME trial. Includes expert commentary.

No Heart Failure Risk With DPP-4 Inhibitor, Sitagliptin, in TECOS Subanalysis

Top

Data from a subanalysis of TECOS at ESC Congress 2015 confirms that the DPP-4 inhibitor, sitagliptin, does not cause heart failure in patients with type 2 diabetes. Includes expert commentary.

NDEI.org Expert Commentary Silvio Inzucchi MD on TECOS Subanalysis No Heart Failure Risk With Sitagliptin in High-Risk Type 2 Diabetes

Top

Silvio Inzucchi, MD, provides expert commentary on data from a subanalysis of TECOS, which confirmed that the DPP-4 inhibitor, sitagliptin, does not cause heart failure in patients with type 2 diabetes; from ESC Congress 2015.

NDEI.org Expert Commentary Vivian Fonseca MD on Results of ELIXA the First Cardiovascular Safety Study to Report Outcomes With A GLP-1 Receptor Agonist

Top

In this diabetes expert blog, Vivian Fonseca, MD, provides insights on results of the ELIXA cardiovascular safety study of the novel (at time of publishing) GLP-1 receptor agonist, lixisenatide.

NDEI.org Expert Commentary Vivian Fonseca, MD, on Results of TECOS, the Cardiovascular Safety Study of the DPP-4 Inhibitor Sitagliptin

Top

Vivian Fonseca provides expert insights on results of the TECOS cardiovascular safety study of the DPP-4 inhibitor, sitagliptin

ADA 2015: The 75th Scientific Sessions of the American Diabetes Association

Top

Coverage of data from ADA 2015, June 5-9, 2015 in Boston, Massachusetts

NDEI.org Expert Commentary SAVOR-TIMI 53 Commentary from Silvio Inzucchi

Top

NDEI Education Council Member Silvio E. Inzucchi MD, comments on SAVOR TIMI 53: "Reassurance of the Overall Cardiovascular Safety of Saxagliptin and, One Might Infer, Other DPP 4 Inhibitors"



Slide Library Results

Search Results for: SAVOR-TIMI 53 Slides Found: 19
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD Secondary Endpoint
SAVOR-TIMI 53: Saxagliptin Increased Hospitalization for Heart Failure
SAVOR-TIMI 53: Significantly Better Glycemic Control with Saxagliptin
SAVOR-TIMI 53: Safety Endpoints
SAVOR-TIMI 53: Design
SAVOR TIMI Saxagliptin Pancreatitis | NDEI
SAVOR TIMI 53 Pancreatitis Risk Factors Saxagliptin DPP-4 | NDEI
No Pancreatic Cancer Signal Saxagliptin DPP-4 SAVOR TIMI | NDEI
SAVOR TIMI 53 Pancreatitis Cancer Saxagliptin DPP-4 | NDEI
Incretins Therapies & Heart Failure Risk in Type 2 Diabetes PPT | NDEI
TECOS Heart Failure Sitaliptin DPP-4 CV Safety | NDEI
Efficacy and Safety of Saxagliptin in Older Adults in SAVOR-TIMI 53
No Increased Ischemic Events With Saxagliptin Vs Placebo in Older Adults in SAVOR-TIMI 53
Mean A1C Reduction With Saxagliptin in Older Adults in SAVOR-TIMI 53
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD
Saxagliptin Not Associated With Fractures in SAVOR-TIMI 53 Analysis | NDEI
Relationship Between DPP-4 Inhibitors & Heart Failure Diabetes | NDEI
Effect of DPP-4 Inhibitors Vs Placebo on Heart Failure in Diabetes | NDEI
SAVOR-TIMI 53 Saxagliptin Not Associated With Fracture Risk Diabetes | NDEI